Comments
Loading...

Sunshine Biopharma

SBFMNASDAQ
Logo brought to you by Benzinga Data
$2.79
-0.31-10.00%
At close: -
$2.78
-0.00990-0.35%
After Hours: 4:00 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$2.60
Lowest Price Target1
$2.60
Consensus Price Target1
$2.60

Sunshine Biopharma (NASDAQ:SBFM) Stock, Analyst Ratings, Price Targets, Forecasts

Sunshine Biopharma Inc has a consensus price target of $2.6 based on the ratings of 1 analysts. The high is $2.6 issued by Aegis Capital on August 7, 2023. The low is $2.6 issued by Aegis Capital on August 7, 2023. The 1 most-recent analyst ratings were released by Aegis Capital on August 7, 2023, respectively. With an average price target of $2.6 between Aegis Capital, there's an implied -6.48% downside for Sunshine Biopharma Inc from these most-recent analyst ratings.

Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Aegis Capital

1calculated from analyst ratings

Analyst Ratings for Sunshine Biopharma

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Sunshine Biopharma (SBFM) stock?

A

The latest price target for Sunshine Biopharma (NASDAQ:SBFM) was reported by Aegis Capital on August 7, 2023. The analyst firm set a price target for $2.60 expecting SBFM to fall to within 12 months (a possible -6.48% downside). 0 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Sunshine Biopharma (SBFM)?

A

The latest analyst rating for Sunshine Biopharma (NASDAQ:SBFM) was provided by Aegis Capital, and Sunshine Biopharma initiated their buy rating.

Q

When was the last upgrade for Sunshine Biopharma (SBFM)?

A

There is no last upgrade for Sunshine Biopharma

Q

When was the last downgrade for Sunshine Biopharma (SBFM)?

A

There is no last downgrade for Sunshine Biopharma.

Q

When is the next analyst rating going to be posted or updated for Sunshine Biopharma (SBFM)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sunshine Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sunshine Biopharma was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

Q

Is the Analyst Rating Sunshine Biopharma (SBFM) correct?

A

While ratings are subjective and will change, the latest Sunshine Biopharma (SBFM) rating was a initiated with a price target of $0.00 to $2.60. The current price Sunshine Biopharma (SBFM) is trading at is $2.78, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch